TARGETED RADIOTHERAPY
    1.
    发明申请
    TARGETED RADIOTHERAPY 有权
    目标放射治疗

    公开(公告)号:US20110038795A1

    公开(公告)日:2011-02-17

    申请号:US12744798

    申请日:2008-11-26

    IPC分类号: A61K51/04 A61P35/00

    CPC分类号: A61K51/04

    摘要: The present invention concerns a therapeutically labeled napthodianthrone or phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound, which comprises a chemical element or an isotope that has an unstable nucleus and emits radiation during its decay to a stable form sufficient to destroy neighboring cells or tissues for use in a targeted radiotherapy to enhance curability of a warm-blooded animal that has been subjected to a necrosis-inducing antitumor therapy. A particular advantage of present invention is that viable rim resistant to a necrosis-inducing antitumor therapy such as vascular targeting agent (VTA) can be supplemented by one single or repeated doses of a therapeutically radiolabeled small molecule necrosis-avid chemical compound treatment to enhance the curability. Examples of necrosis inducing therapies are for instance minimally invasive tumor ablations applied chemically by percutaneous injection of ethanol or acetic acid, or physically by cryotherapy, microwave, focused ultrasound, interstitial laser therapy and radio-frequency ablation (RFA); by chemotherapies using cytotoxic agents or vascular targeting agents (VTA); and by external or internal radiotherapies.

    摘要翻译: 本发明涉及一种治疗上标记的阴蒂龙酮或菲咯啉[1,10,9,8-吖庚因]二萘嵌苯-7,14-二酮化合物,其包含具有不稳定核的化学元素或同位素,并在其衰变期间发射辐射 足以破坏用于靶向放射治疗的相邻细胞或组织的稳定形式,以增强已经进行坏死诱导的抗肿瘤治疗的温血动物的固化性。 本发明的一个特别优点是可以通过一种单独或重复剂量的治疗性放射性标记的小分子坏死的化学化合物治疗来补充对坏死诱导的抗肿瘤治疗如血管靶向剂(VTA)有抗性的活性边缘,以增强 固化性 坏死诱导疗法的实例是例如通过经皮注射乙醇或乙酸而化学施用的微创肿瘤消融,或通过冷冻治疗,微波,聚焦超声,间质激光治疗和射频消融(RFA)物理化学进行的微创肿瘤消融。 通过使用细胞毒剂或血管靶向剂(VTA)的化疗; 以及外部或内部放射治疗。

    Cooled-wet electrode
    2.
    发明授权
    Cooled-wet electrode 失效
    冷却电极

    公开(公告)号:US06514251B1

    公开(公告)日:2003-02-04

    申请号:US09762728

    申请日:2001-05-01

    IPC分类号: A61B1818

    摘要: Device for delivering radio frequency (RF) energy, for example during tissue ablation procedures, comprising an electrode having a distal end associated with tissue puncturing means and a proximal end connectable to a radio frequency energy source, wetting means for wetting the proximity of the distal end of the electrode with a non-toxic (RF) conductive solution and cooling means for cooling at least the distal end of the electrode. The invention further relates to a process for cooling and wetting a radio frequency energy delivering device and to a guidance element therefor.

    摘要翻译: 用于递送射频(RF)能量的装置,例如在组织消融过程期间,包括具有与组织穿刺装置相关联的远端的电极和可连接到射频能量源的近端,用于润湿远端 末端具有无毒(RF)导电溶液和冷却装置,用于至少冷却电极的远端。 本发明还涉及一种用于冷却和润湿射频能量输送装置及其引导元件的方法。

    Targeted radiotherapy
    3.
    发明授权
    Targeted radiotherapy 有权
    靶向放疗

    公开(公告)号:US08741262B2

    公开(公告)日:2014-06-03

    申请号:US12744798

    申请日:2008-11-26

    IPC分类号: A61K51/00 A61K49/04

    CPC分类号: A61K51/04

    摘要: The present invention concerns a therapeutically labeled napthodianthrone or phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound, which comprises a chemical element or an isotope that has an unstable nucleus and emits radiation during its decay to a stable form sufficient to destroy neighboring cells or tissues for use in a targeted radiotherapy to enhance curability of a warm-blooded animal that has been subjected to a necrosis-inducing antitumor therapy. A particular advantage of present invention is that viable rim resistant to a necrosis-inducing antitumor therapy such as vascular targeting agent (VTA) can be supplemented by one single or repeated doses of a therapeutically radiolabeled small molecule necrosis-avid chemical compound treatment to enhance the curability. Examples of necrosis inducing therapies are for instance minimally invasive tumor ablations applied chemically by percutaneous injection of ethanol or acetic acid, or physically by cryotherapy, microwave, focused ultrasound, interstitial laser therapy and radio-frequency ablation (RFA); by chemotherapies using cytotoxic agents or vascular targeting agents (VTA); and by external or internal radiotherapies.

    摘要翻译: 本发明涉及一种治疗上标记的阴蒂龙酮或菲咯啉[1,10,9,8-吖庚因]二萘嵌苯-7,14-二酮化合物,其包含具有不稳定核的化学元素或同位素,并在其衰变期间发射辐射 足以破坏用于靶向放射治疗的相邻细胞或组织的稳定形式,以增强已经进行坏死诱导的抗肿瘤治疗的温血动物的固化性。 本发明的一个特别优点是可以通过一种单独或重复剂量的治疗性放射性标记的小分子坏死化学化合物治疗来补充对坏死诱导的抗肿瘤治疗如血管靶向剂(VTA)有抗性的活性边缘,以增强 固化性 坏死诱导疗法的实例是例如通过经皮注射乙醇或乙酸而化学施用的微创肿瘤消融,或通过冷冻治疗,微波,聚焦超声,间质激光治疗和射频消融(RFA)物理化学进行的微创肿瘤消融。 通过使用细胞毒剂或血管靶向剂(VTA)的化疗; 以及外部或内部放射治疗。

    NECROSIS AVID TRACER AGENT
    5.
    发明申请
    NECROSIS AVID TRACER AGENT 审中-公开
    NECROSIS AVID追踪器代理

    公开(公告)号:US20090274622A1

    公开(公告)日:2009-11-05

    申请号:US12502060

    申请日:2009-07-13

    IPC分类号: A61K51/04 A61K49/10

    CPC分类号: A61K31/122 A61K51/0406

    摘要: The invention relates to a method for obtaining an image of ischemic, infarcted or necrotic tissue in a subject, comprising the step of administering an imaging agent comprising a phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound. For example, the invention concerns to the use of phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives, and more specifically hypericin or its derivatives, as necrosis or infarct specific agents. The phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives can be labeled with a radionuclide, a radiopaque material or a material enhancing the effects magnetic resonance imaging. The invention further features a pharmaceutical composition comprising a phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound optionally conjugated to a radionuclide or a radiopaque material, provided that said phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound is not mono-[123I]-iodohypericin.

    摘要翻译: 本发明涉及一种用于获得受试者中缺血性,梗死或坏死组织的图像的方法,包括给予包含菲并[1,10,9,8-吖庚因]苝-7,14-二酮的显像剂的步骤 复合。 例如,本发明涉及菲咯啉[1,10,9,8-吖庚因]二萘嵌苯-7,14-二酮衍生物,更具体地涉及金丝桃素或其衍生物作为坏死或梗死特异性试剂的用途。 菲咯啉[1,10,9,8-opqra]苝-7,14-二酮衍生物可用放射性核素,不透射线材料或增强磁共振成像效果的材料进行标记。 本发明进一步具有药物组合物,其包含任选地与放射性核素缀合的菲咯啉[1,10,9,8-吖庚因]苝-7,14-二酮化合物或不透射线的材料,条件是所述菲并[1,10,9, 8-opqra]苝-7,14-二酮化合物不是单 - [123 I]碘碘霉素。

    Necrosis avid tracer agent
    6.
    发明申请
    Necrosis avid tracer agent 审中-公开
    坏死狂犬病病例

    公开(公告)号:US20070122340A1

    公开(公告)日:2007-05-31

    申请号:US10595062

    申请日:2004-07-23

    IPC分类号: A61K51/00 A61K49/04

    CPC分类号: A61K31/122 A61K51/0406

    摘要: The present invention concerns to the use of phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives, and more specifically hypericin or its derivatives, as necrosis or infarct specific agents. The phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives can be labeled with a radionuclide, a radiopaque material or a material enhancing the effects magnetic resonance imaging.

    摘要翻译: 本发明涉及菲咯啉[1,10,9,8-opqra]苝-7,14-二酮衍生物,更具体地涉及金丝桃素或其衍生物作为坏死或梗塞特异性试剂的用途。 菲咯啉[1,10,9,8-opqra]苝-7,14-二酮衍生物可用放射性核素,不透射线材料或增强磁共振成像效果的材料进行标记。

    Method and assembly for recording a radiation image of an elongate body
    7.
    发明授权
    Method and assembly for recording a radiation image of an elongate body 有权
    用于记录细长体的辐射图像的方法和组件

    公开(公告)号:US06273606B1

    公开(公告)日:2001-08-14

    申请号:US09201981

    申请日:1998-12-01

    IPC分类号: G03B4204

    CPC分类号: A61B6/5241 A61B6/4291

    摘要: An assembly for recording a radiation image of an elongate body comprises a plurality of cassettes each conveying a recording member and each having a length that is smaller than the length of the elongate body. Supporting devices are arranged for holding the plurality of cassettes in a staggered arrangement so that the length of the staggered arrangement is at least equal to the length of the elongate body. This assembly is exposed to the radiation image of an elongate body. By use of partial images which are read from each of the recording members, the entire image of the elongate body is reconstructed.

    摘要翻译: 用于记录细长体的放射线图像的组件包括多个盒,每个盒都传送记录构件,每个盒的长度小于细长体的长度。 支撑装置被布置成用于将多个盒子保持为交错布置,使得交错布置的长度至少等于细长主体的长度。 该组件暴露于细长主体的辐射图像。 通过使用从每个记录部件读取的部分图像,重建细长主体的整个图像。